AIMS/HYPOTHESIS: Using a mouse model of lipoatrophic diabetes, we hypothesised that the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) pathway contributes to hepatic macrophage accumulation and insulin resistance through induction of a chronic inflammatory state. METHODS: Metabolic variables of insulin resistance and inflammation were characterised in wild-type and lipoatrophic A-ZIP/F-1 transgenic (AZIP-Tg) mice. The AZIP-Tg mice were then treated with a CCR2 antagonist (RS504393, 2 mg kg(-1) day(-1)) or vehicle for 28 days via a subcutaneous mini-osmotic pump to examine the role of the CCL2/CCR2 pathway in lipoatrophic diabetes. RESULTS: The lipoatrophic AZIP-Tg mice were diabetic with high fasting glucose and serum insulin concentrations compared with littermate controls. The livers of AZIP-Tg mice were more than threefold enlarged and exhibited increased triacylglycerol content. CCL2 levels were highly elevated in both liver and serum of the AZIP-Tg mice compared with controls. In addition, the circulating CCL2 concentration was associated with increased macrophage accumulation and inflammation as documented by upregulation of Cd68 gene and Tnf-alpha [also known as Tnf] gene in livers from the AZIP-Tg mice. Treatment of the lipoatrophic AZIP-Tg mice with the CCR2 antagonist ameliorated the hyperglycaemia, hyperinsulinaemia and hepatomegaly in conjunction with a reduction in liver inflammation. CONCLUSIONS/ INTERPRETATION: These findings demonstrate a significant role of the CCL2/CCR2 pathway in lipoatrophy-induced diabetes and provide clear evidence that metabolic improvements resulting from the inhibition of this inflammatory pathway are not adipose tissue-dependent.
AIMS/HYPOTHESIS: Using a mouse model of lipoatrophic diabetes, we hypothesised that the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) pathway contributes to hepatic macrophage accumulation and insulin resistance through induction of a chronic inflammatory state. METHODS: Metabolic variables of insulin resistance and inflammation were characterised in wild-type and lipoatrophic A-ZIP/F-1 transgenic (AZIP-Tg) mice. The AZIP-Tgmice were then treated with a CCR2 antagonist (RS504393, 2 mg kg(-1) day(-1)) or vehicle for 28 days via a subcutaneous mini-osmotic pump to examine the role of the CCL2/CCR2 pathway in lipoatrophic diabetes. RESULTS: The lipoatrophic AZIP-Tgmice were diabetic with high fasting glucose and serum insulin concentrations compared with littermate controls. The livers of AZIP-Tgmice were more than threefold enlarged and exhibited increased triacylglycerol content. CCL2 levels were highly elevated in both liver and serum of the AZIP-Tgmice compared with controls. In addition, the circulating CCL2 concentration was associated with increased macrophage accumulation and inflammation as documented by upregulation of Cd68 gene and Tnf-alpha [also known as Tnf] gene in livers from the AZIP-Tgmice. Treatment of the lipoatrophic AZIP-Tgmice with the CCR2 antagonist ameliorated the hyperglycaemia, hyperinsulinaemia and hepatomegaly in conjunction with a reduction in liver inflammation. CONCLUSIONS/ INTERPRETATION: These findings demonstrate a significant role of the CCL2/CCR2 pathway in lipoatrophy-induced diabetes and provide clear evidence that metabolic improvements resulting from the inhibition of this inflammatory pathway are not adipose tissue-dependent.
Authors: John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust Journal: J Hepatol Date: 2006-03-20 Impact factor: 25.083
Authors: C Herder; J Baumert; B Thorand; W Koenig; W de Jager; C Meisinger; T Illig; S Martin; H Kolb Journal: Diabetologia Date: 2006-03-11 Impact factor: 10.122
Authors: C-S Kim; H-S Park; T Kawada; J-H Kim; D Lim; N E Hubbard; B-S Kwon; K L Erickson; R Yu Journal: Int J Obes (Lond) Date: 2006-03-14 Impact factor: 5.095
Authors: Jukka Westerbacka; Maria Kolak; Tuula Kiviluoto; Perttu Arkkila; Jukka Sirén; Anders Hamsten; Rachel M Fisher; Hannele Yki-Järvinen Journal: Diabetes Date: 2007-08-17 Impact factor: 9.461
Authors: Kaifeng Lisa Lin; Shari Sweeney; Brian Donghoon Kang; Elizabeth Ramsburg; Michael Dee Gunn Journal: J Immunol Date: 2010-11-22 Impact factor: 5.422
Authors: Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco Journal: World J Gastroenterol Date: 2012-02-28 Impact factor: 5.742
Authors: Richard Parker; Christopher J Weston; Zhenhua Miao; Christopher Corbett; Matthew J Armstrong; Linda Ertl; Karen Ebsworth; Matthew J Walters; Trageen Baumart; Dale Newland; Jeff McMahon; Penglie Zhang; Rajinder Singh; James Campbell; Philip N Newsome; Israel Charo; Thomas J Schall; David H Adams Journal: Am J Physiol Gastrointest Liver Physiol Date: 2018-02-08 Impact factor: 4.052
Authors: L Longobardi; J D Temple; L Tagliafierro; H Willcockson; A Esposito; N D'Onofrio; E Stein; T Li; T J Myers; H Ozkan; M L Balestrieri; V Ulici; R F Loeser; A Spagnoli Journal: Osteoarthritis Cartilage Date: 2016-11-14 Impact factor: 6.576
Authors: Y Nio; T Yamauchi; M Iwabu; M Okada-Iwabu; M Funata; M Yamaguchi; K Ueki; T Kadowaki Journal: Diabetologia Date: 2012-09-16 Impact factor: 10.122
Authors: Timothy Sullivan; Zhenhua Miao; Daniel J Dairaghi; Antoni Krasinski; Yu Wang; Bin N Zhao; Trageen Baumgart; Linda S Ertl; Andrew Pennell; Lisa Seitz; Jay Powers; Ruiping Zhao; Solomon Ungashe; Zheng Wei; Landin Boring; Chia-Lin Tsou; Israel Charo; Robert D Berahovich; Thomas J Schall; Juan C Jaen Journal: Am J Physiol Renal Physiol Date: 2013-08-28
Authors: Amrom E Obstfeld; Eiji Sugaru; Marie Thearle; Anne-Marie Francisco; Constance Gayet; Henry N Ginsberg; Eleanore V Ables; Anthony W Ferrante Journal: Diabetes Date: 2010-01-26 Impact factor: 9.461